GRITSTONE BIO INC (GRTS) Stock Price & Overview
NASDAQ:GRTS • US39868T1051
Current stock price
The current stock price of GRTS is 0.0322 USD. Today GRTS is down by -31.78%. In the past month the price decreased by -94.46%. In the past year, price decreased by -98.3%.
GRTS Key Statistics
- Market Cap
- 3.803M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.09
- Dividend Yield
- N/A
GRTS Stock Performance
GRTS Stock Chart
GRTS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GRTS. When comparing the yearly performance of all stocks, GRTS is a bad performer in the overall market: 99.93% of all stocks are doing better.
GRTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRTS. GRTS has a bad profitability rating. Also its financial health evaluation is rather negative.
GRTS Earnings
On August 13, 2024 GRTS reported an EPS of -0.16 and a revenue of 921.00K. The company beat EPS expectations (44.55% surprise) and missed revenue expectations (-34.21% surprise).
GRTS Forecast & Estimates
6 analysts have analysed GRTS and the average price target is 0.77 USD. This implies a price increase of 2275.78% is expected in the next year compared to the current price of 0.0322.
For the next year, analysts expect an EPS growth of 19.29% and a revenue growth -74.34% for GRTS
GRTS Groups
Sector & Classification
GRTS Financial Highlights
Over the last trailing twelve months GRTS reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS increased by 13.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.33% | ||
| ROE | -599.53% | ||
| Debt/Equity | 1.83 |
GRTS Ownership
GRTS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.9 | 368.381B | ||
| AMGN | AMGEN INC | 15.33 | 189.472B | ||
| GILD | GILEAD SCIENCES INC | 15.96 | 175.4B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.63 | 114.717B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.77 | 78.668B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.7 | 41.749B | ||
| INSM | INSMED INC | N/A | 30.759B | ||
| NTRA | NATERA INC | N/A | 28.033B | ||
| BIIB | BIOGEN INC | 11.41 | 26.756B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.64 | 23.245B | ||
| MRNA | MODERNA INC | N/A | 20.695B | ||
| EXAS | EXACT SCIENCES CORP | 341.89 | 19.805B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.443B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRTS
Company Profile
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 231 full-time employees. The company went IPO on 2018-09-28. The firm discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. The company has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The company has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
Company Info
IPO: 2018-09-28
GRITSTONE BIO INC
5959 Horton Street, Suite 300
Emeryville CALIFORNIA 94608 US
CEO: Andrew Allen
Employees: 231
Phone: 15108716100
GRITSTONE BIO INC / GRTS FAQ
What does GRITSTONE BIO INC do?
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 231 full-time employees. The company went IPO on 2018-09-28. The firm discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. The company has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The company has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
Can you provide the latest stock price for GRITSTONE BIO INC?
The current stock price of GRTS is 0.0322 USD. The price decreased by -31.78% in the last trading session.
Does GRTS stock pay dividends?
GRTS does not pay a dividend.
How is the ChartMill rating for GRITSTONE BIO INC?
GRTS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for GRTS stock?
6 analysts have analysed GRTS and the average price target is 0.77 USD. This implies a price increase of 2275.78% is expected in the next year compared to the current price of 0.0322.
What sector and industry does GRITSTONE BIO INC belong to?
GRITSTONE BIO INC (GRTS) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for GRITSTONE BIO INC?
GRITSTONE BIO INC (GRTS) will report earnings on 2024-11-07, after the market close.